50 related articles for article (PubMed ID: 33547213)
1. Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.
Bodet-Milin C; Faivre-Chauvet A; Carlier T; Ansquer C; Rauscher A; Frampas E; Toulgoat F; Masson D; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
J Nucl Med; 2021 Sep; 62(9):1221-1227. PubMed ID: 33547213
[TBL] [Abstract][Full Text] [Related]
2. Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches.
Bodet-Milin C; Bailly C; Touchefeu Y; Frampas E; Bourgeois M; Rauscher A; Lacoeuille F; Drui D; Arlicot N; Goldenberg DM; Faivre-Chauvet A; Barbet J; Rousseau C; Kraeber-Bodéré F
Front Med (Lausanne); 2019; 6():124. PubMed ID: 31214593
[TBL] [Abstract][Full Text] [Related]
3. Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside.
Li L; Lin X; Wang L; Ma X; Zeng Z; Liu F; Jia B; Zhu H; Wu A; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3735-3749. PubMed ID: 37382662
[TBL] [Abstract][Full Text] [Related]
4. Sensitivities evaluation of five radiopharmaceuticals in four common medullary thyroid carcinoma metastatic sites on PET/CT: a network meta-analysis and systematic review.
Li P; Zhang Y; Xu T; Zhu J; Wei T; Zhao W
Nucl Med Commun; 2023 Dec; 44(12):1114-1125. PubMed ID: 37769014
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of pretargeted immunoPET using
Foubert F; Gouard S; Saï-Maurel C; Chérel M; Faivre-Chauvet A; Goldenberg DM; Barbet J; Bailly C; Bodet-Milin C; Carlier T; Kraeber-Bodéré F; Touchefeu Y; Frampas E
Oncotarget; 2018 Jun; 9(44):27502-27513. PubMed ID: 29938001
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head comparison between [
He Q; Zhang Z; Zhang L; Zhang B; Long Y; Zhang Y; Liao Z; Zha Z; Zhang X
Eur J Nucl Med Mol Imaging; 2024 Feb; ():. PubMed ID: 38300262
[TBL] [Abstract][Full Text] [Related]
7. [Not Available].
Domenech Brasero B; Mestre-Fusco A; Suárez Piñera M; Puertas Calvo E; Perich Alsina X; Montes G; Plaza López P
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020 Dec; ():. PubMed ID: 33388292
[TBL] [Abstract][Full Text] [Related]
8. Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues.
Raia S; Chiloiro S; Giampietro A; Maratta MG; Attili F; Brizi MG; Rufini V; De Marinis L; Pontecorvi A; Rindi G; Schinzari G; Bianchi A
Endocr Metab Immune Disord Drug Targets; 2024 Jan; ():. PubMed ID: 38284724
[TBL] [Abstract][Full Text] [Related]
9. Amino Acid PET Imaging with
Djekidel M; Alsadi R; Bouhali O; Maaz AUR
J Nucl Med Technol; 2022 Apr; ():. PubMed ID: 35440479
[TBL] [Abstract][Full Text] [Related]
10. Biological characterization of renal masses using immuno-PET.
Gelardi F; Larcher A; Antunovic L; Capitanio U; Salonia A; Chiti A
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38730085
[No Abstract] [Full Text] [Related]
11. Evaluation of
Daniel KB; de Oliveira Santos A; de Andrade RA; Trentin MBF; Garmes HM
J Endocrinol Invest; 2021 Oct; 44(10):2195-2202. PubMed ID: 33569721
[TBL] [Abstract][Full Text] [Related]
12. A head-to-head comparison of
Qin C; Liu F; Huang J; Ruan W; Liu Q; Gai Y; Hu F; Jiang D; Hu Y; Yang K; Lan X
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3228-3237. PubMed ID: 33609152
[TBL] [Abstract][Full Text] [Related]
13. Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.
Windisch P; Zwahlen DR; Giesel FL; Scholz E; Lugenbiel P; Debus J; Haberkorn U; Adeberg S
EJNMMI Res; 2021 Feb; 11(1):18. PubMed ID: 33606104
[TBL] [Abstract][Full Text] [Related]
14. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.
Ceci F; Oprea-Lager DE; Emmett L; Adam JA; Bomanji J; Czernin J; Eiber M; Haberkorn U; Hofman MS; Hope TA; Kumar R; Rowe SP; Schwarzenboeck SM; Fanti S; Herrmann K
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1626-1638. PubMed ID: 33604691
[TBL] [Abstract][Full Text] [Related]
15. Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.
Frood R; Burton C; Tsoumpas C; Frangi AF; Gleeson F; Patel C; Scarsbrook A
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3198-3220. PubMed ID: 33604689
[TBL] [Abstract][Full Text] [Related]
16. Quantitative
Ortega C; Wong RKS; Schaefferkoetter J; Veit-Haibach P; Myrehaug S; Juergens R; Laidley D; Anconina R; Liu A; Metser U
J Nucl Med; 2021 Oct; 62(10):1406-1414. PubMed ID: 33579805
[TBL] [Abstract][Full Text] [Related]
17. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT.
Duell J; Krummenast F; Schirbel A; Klassen P; Samnick S; Rauert-Wunderlich H; Rasche L; Buck AK; Wester HJ; Rosenwald A; Einsele H; Topp MS; Lapa C; Kircher M
J Nucl Med; 2021 Oct; 62(10):1415-1421. PubMed ID: 33579803
[TBL] [Abstract][Full Text] [Related]
18.
Liberini V; Rampado O; Gallio E; De Santi B; Ceci F; Dionisi B; Thuillier P; Ciuffreda L; Piovesan A; Fioroni F; Versari A; Molinari F; Deandreis D
Front Med (Lausanne); 2020; 7():601853. PubMed ID: 33575262
[No Abstract] [Full Text] [Related]
19. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.
Skånland SS; Mato AR
Blood Adv; 2021 Jan; 5(1):334-343. PubMed ID: 33570649
[TBL] [Abstract][Full Text] [Related]
20. 68Ga-Prostate-specific membrane antigen (psma) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis.
Matushita CS; da Silva AMM; Schuck PN; Bardisserotto M; Piant DB; Pereira JL; Cerci JJ; Coura-Filho GB; Esteves FP; Amorim BJ; Gomes GV; Brito AET; Bernardo WM; Mundstock E; Fanti S; Macedo B; Roman DH; Tem-Pass CS; Hochhegger B
Int Braz J Urol; 2021; 47(4):705-729. PubMed ID: 33566470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
